Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study.
Aurora ZanghìGiovanna BorrielloSimona BonavitaRoberta FantozziElisabetta SignorielloStefania BaroneGianmarco AbbadessaMaria CellerinoVanessa ZicconeGiuseppina MieleGiacomo LusPaola ValentinoSebastiano BucelloMatilde IngleseDiego CentonzeCarlo AvolioEmanuele D'AmicoPublished in: Journal of neurology (2024)
The treatment with OCR and OFA resulted in comparable control of disease activity with good safety profile. Our results need further validation in larger multicentre studies with long-term follow-up.